Novel high-sensitive D-Dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients

Patrizia Ferroni, Francesca Martini, Ilaria Portarena, Gioia Massimiani, Silvia Riondino, Francesca La Farina, Sabrina Mariotti, Fiorella Guadagni, Mario Roselli

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: We hypothesized that the use of a novel high sensitivity (HS) assay for D-dimer determination might ameliorate venous thromboembolism (VTE) risk prediction in intermediate risk lung cancer patients in whom chemotherapy could act as a trigger for VTE onset. Patients and Methods: Pretreatment HS D-dimer levels were retrospectively evaluated in 108 lung cancer outpatients using a novel automated latex enhanced turbidimetric immunoassay. All patients were at the start of a new platinum-based chemotherapy regimen and were classified as intermediate risk according to Khorana's assessment model. Patients were followed-up for a median period of 6.9 months. Results: Receiver operating characteristic (ROC) curves and corresponding Bayesian analysis showed that the best performance was obtained at a cutoff level of 1500 ng/mL, which resulted in a sensitivity of 81%, a specificity of 69%, a positive predictive value (PPV) of 31%, a negative predictive value (NPV) of 96%, and an accuracy of 70%. Patients with HS D-dimer levels above the cutoff had a worse VTE-free survival (60%) compared with those with levels below the cutoff (95%; P =.0001). Multivariate Cox proportional hazards survival analysis confirmed that pretreatment HS D-dimer levels were able to significantly predict VTE with a hazard ratio of 11 (95% confidence interval, 2.62-46.2; P =.001), independently of classic VTE risk factors. Conclusions: The use of HS D-dimer determination prior to chemotherapy might allow for VTE risk stratification of intermediate risk cancer patients, helping in identifying those individuals who could benefit from thromboprophylaxis.

Original languageEnglish
Pages (from-to)482-487
Number of pages6
JournalClinical Lung Cancer
Volume13
Issue number6
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Venous Thromboembolism
Lung Neoplasms
Drug Therapy
Bayes Theorem
Latex
Survival Analysis
Platinum
Immunoassay
ROC Curve
fibrin fragment D
Outpatients
Confidence Intervals
Survival
Neoplasms

Keywords

  • Biomarkers
  • Coagulation
  • Risk assessment
  • Risk prediction
  • Thromboprophylaxis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Novel high-sensitive D-Dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. / Ferroni, Patrizia; Martini, Francesca; Portarena, Ilaria; Massimiani, Gioia; Riondino, Silvia; La Farina, Francesca; Mariotti, Sabrina; Guadagni, Fiorella; Roselli, Mario.

In: Clinical Lung Cancer, Vol. 13, No. 6, 11.2012, p. 482-487.

Research output: Contribution to journalArticle

Ferroni, Patrizia ; Martini, Francesca ; Portarena, Ilaria ; Massimiani, Gioia ; Riondino, Silvia ; La Farina, Francesca ; Mariotti, Sabrina ; Guadagni, Fiorella ; Roselli, Mario. / Novel high-sensitive D-Dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. In: Clinical Lung Cancer. 2012 ; Vol. 13, No. 6. pp. 482-487.
@article{5189b7ee427d48c0b82447408edcf6d8,
title = "Novel high-sensitive D-Dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients",
abstract = "Introduction: We hypothesized that the use of a novel high sensitivity (HS) assay for D-dimer determination might ameliorate venous thromboembolism (VTE) risk prediction in intermediate risk lung cancer patients in whom chemotherapy could act as a trigger for VTE onset. Patients and Methods: Pretreatment HS D-dimer levels were retrospectively evaluated in 108 lung cancer outpatients using a novel automated latex enhanced turbidimetric immunoassay. All patients were at the start of a new platinum-based chemotherapy regimen and were classified as intermediate risk according to Khorana's assessment model. Patients were followed-up for a median period of 6.9 months. Results: Receiver operating characteristic (ROC) curves and corresponding Bayesian analysis showed that the best performance was obtained at a cutoff level of 1500 ng/mL, which resulted in a sensitivity of 81{\%}, a specificity of 69{\%}, a positive predictive value (PPV) of 31{\%}, a negative predictive value (NPV) of 96{\%}, and an accuracy of 70{\%}. Patients with HS D-dimer levels above the cutoff had a worse VTE-free survival (60{\%}) compared with those with levels below the cutoff (95{\%}; P =.0001). Multivariate Cox proportional hazards survival analysis confirmed that pretreatment HS D-dimer levels were able to significantly predict VTE with a hazard ratio of 11 (95{\%} confidence interval, 2.62-46.2; P =.001), independently of classic VTE risk factors. Conclusions: The use of HS D-dimer determination prior to chemotherapy might allow for VTE risk stratification of intermediate risk cancer patients, helping in identifying those individuals who could benefit from thromboprophylaxis.",
keywords = "Biomarkers, Coagulation, Risk assessment, Risk prediction, Thromboprophylaxis",
author = "Patrizia Ferroni and Francesca Martini and Ilaria Portarena and Gioia Massimiani and Silvia Riondino and {La Farina}, Francesca and Sabrina Mariotti and Fiorella Guadagni and Mario Roselli",
year = "2012",
month = "11",
doi = "10.1016/j.cllc.2012.03.005",
language = "English",
volume = "13",
pages = "482--487",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Novel high-sensitive D-Dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients

AU - Ferroni, Patrizia

AU - Martini, Francesca

AU - Portarena, Ilaria

AU - Massimiani, Gioia

AU - Riondino, Silvia

AU - La Farina, Francesca

AU - Mariotti, Sabrina

AU - Guadagni, Fiorella

AU - Roselli, Mario

PY - 2012/11

Y1 - 2012/11

N2 - Introduction: We hypothesized that the use of a novel high sensitivity (HS) assay for D-dimer determination might ameliorate venous thromboembolism (VTE) risk prediction in intermediate risk lung cancer patients in whom chemotherapy could act as a trigger for VTE onset. Patients and Methods: Pretreatment HS D-dimer levels were retrospectively evaluated in 108 lung cancer outpatients using a novel automated latex enhanced turbidimetric immunoassay. All patients were at the start of a new platinum-based chemotherapy regimen and were classified as intermediate risk according to Khorana's assessment model. Patients were followed-up for a median period of 6.9 months. Results: Receiver operating characteristic (ROC) curves and corresponding Bayesian analysis showed that the best performance was obtained at a cutoff level of 1500 ng/mL, which resulted in a sensitivity of 81%, a specificity of 69%, a positive predictive value (PPV) of 31%, a negative predictive value (NPV) of 96%, and an accuracy of 70%. Patients with HS D-dimer levels above the cutoff had a worse VTE-free survival (60%) compared with those with levels below the cutoff (95%; P =.0001). Multivariate Cox proportional hazards survival analysis confirmed that pretreatment HS D-dimer levels were able to significantly predict VTE with a hazard ratio of 11 (95% confidence interval, 2.62-46.2; P =.001), independently of classic VTE risk factors. Conclusions: The use of HS D-dimer determination prior to chemotherapy might allow for VTE risk stratification of intermediate risk cancer patients, helping in identifying those individuals who could benefit from thromboprophylaxis.

AB - Introduction: We hypothesized that the use of a novel high sensitivity (HS) assay for D-dimer determination might ameliorate venous thromboembolism (VTE) risk prediction in intermediate risk lung cancer patients in whom chemotherapy could act as a trigger for VTE onset. Patients and Methods: Pretreatment HS D-dimer levels were retrospectively evaluated in 108 lung cancer outpatients using a novel automated latex enhanced turbidimetric immunoassay. All patients were at the start of a new platinum-based chemotherapy regimen and were classified as intermediate risk according to Khorana's assessment model. Patients were followed-up for a median period of 6.9 months. Results: Receiver operating characteristic (ROC) curves and corresponding Bayesian analysis showed that the best performance was obtained at a cutoff level of 1500 ng/mL, which resulted in a sensitivity of 81%, a specificity of 69%, a positive predictive value (PPV) of 31%, a negative predictive value (NPV) of 96%, and an accuracy of 70%. Patients with HS D-dimer levels above the cutoff had a worse VTE-free survival (60%) compared with those with levels below the cutoff (95%; P =.0001). Multivariate Cox proportional hazards survival analysis confirmed that pretreatment HS D-dimer levels were able to significantly predict VTE with a hazard ratio of 11 (95% confidence interval, 2.62-46.2; P =.001), independently of classic VTE risk factors. Conclusions: The use of HS D-dimer determination prior to chemotherapy might allow for VTE risk stratification of intermediate risk cancer patients, helping in identifying those individuals who could benefit from thromboprophylaxis.

KW - Biomarkers

KW - Coagulation

KW - Risk assessment

KW - Risk prediction

KW - Thromboprophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84867565956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867565956&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2012.03.005

DO - 10.1016/j.cllc.2012.03.005

M3 - Article

C2 - 22591606

AN - SCOPUS:84867565956

VL - 13

SP - 482

EP - 487

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -